ALLO

Allogene Therapeutics Inc.

Price

$2.23

return (12m)

112.38%

p/e

-4.00

p/bv

1.52

DIVIDEND YIELD

0.00%

ALLO price

Allogene Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ALLO

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

23.20%

3 months

13.78%

1 year

112.38%

2 years

-15.85%

5 years

-90.49%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ALLO

Valuation

P/E

-4.00

Sector -4.38

Industry -4.38

P/BV

1.52

Sector 2.02

Industry 2.02

P/Revenue (PSR)

142.51

Sector -4.40

Industry -4.40

EV/EBITDA

-8.28

Sector -263.09

Industry -263.09

EV/EBIT

-7.76

Sector -702.90

Industry -702.90

P/EBITDA

-4.34

Sector -4.39

Industry -4.39

P/EBIT

-4.03

Sector -4.73

Industry -4.73

P/Total Assets

1.20

Sector 1.49

Industry 1.49

P/Net Current Assets

2.92

Sector -11.70

Industry -11.70

P/Working Capital

2.15

Sector -3.19

Industry -3.19

EPS

-0.50

Sector -2.14

Industry -2.14

BVPS

1.33

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-855.39%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-912.28%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.01

Sector 0.03

Industry 0.03

Profitability

ROE

-37.94%

Sector -65.14%

Industry -65.14%

ROA

-30.09%

Sector -65.53%

Industry -65.53%

ROIC

-112.80%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

10.72

Sector 2.90

Industry 2.90

Net Debt / EBITDA

8.38

Sector -6.07

Industry -6.07

Net Debt / EBIT

7.86

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.76

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.79

Sector 0.41

Industry 0.41

Liabilities/Assets

0.21

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-47.29%

Sector -

Industry -

5Y Earnings CAGR

-1.89%

Sector -

Industry -

Fundamentals ALLO

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ALLO Allogene Therapeutics Inc.	$2.23	112.38%	0.00%	-4.00	1.52	-37.94%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ALLO Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Allogene Therapeutics

Allogene Therapeutics Inc.

Average Investor10 user rating

4.0 (3 people)

United States

9 years

Founded: 2017

2018

Time since IPO - 8 years

265

Employees

Allogene Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $661.26 million, with shareholders equity totaling $436.18 million.

The company employs approximately 265 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Allogene Therapeutics Inc. reported $4.64 million in revenue, generating net income of $-165.50 million.

Key financial metrics include a P/E ratio of -4.00, a price-to-book (P/B) ratio of 1.52, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ALLO.

Market cap

$661.26 million

Net worth

$436.18 million

$436,180,000.00

Assets

$550.09 million

$550,090,000.00

Total Shares Outstanding

329.00 million

329,000,000

Average Daily Trading Volume

$8.16 million

$8,164,291.46

Sector

Health Care

Industry

Biotechnology

ALLO

ALLO revenue and profits

Financial Results ALLO

DRAG THE FRAME TO SEE MORE DATA

ALLO cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Allogene Therapeutics (ALLO) today?

A cotação de Allogene Therapeutics (ALLO) hoje está em US$ 2.23, com uma variação de 112.38% em relação ao último ano. A cotação de Allogene Therapeutics (ALLO) iniciou o ano negociando na casa dos US$ 1.37 e hoje está em US$ 2.23. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Allogene Therapeutics (ALLO) e dados de ações do Ibovespa e mercados internacionais.

Quando Allogene Therapeutics (ALLO) paga dividendos?

Allogene Therapeutics (ALLO) não distribuiu dividendos no último ano.

Is Allogene Therapeutics (ALLO) a good investment?

Atualmente, Allogene Therapeutics (ALLO) está cotada a US$ 2.23, com um P/L de -4.00, representando um desvio de -232% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 112.38 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 112.38%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Allogene Therapeutics (ALLO) stock?

Investir em ações de Allogene Therapeutics (ALLO) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Allogene Therapeutics (ALLO) yield today?

A rentabilidade de Allogene Therapeutics (ALLO) foi de 23.20% no último mês, 112.38% no último ano e -90.49% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Allogene Therapeutics (ALLO) hoje, o investimento total seria de US$ 223.00, com base na cotação atual de US$ 2.23.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 473.61
Em 5 anos: US$ 21.21
Em 10 anos: US$ 223.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ALLO

Allogene Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ALLO

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING ALLO WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Allogene Therapeutics

Allogene Therapeutics Inc.

United States

9 years

2018

265

PROFIT X PRICE ALLO

Financial Results ALLO

ALLO cash flow

Asset, Revenue and Profit Growth - ALLO

ALLO balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions